Pre-made Gremubamab benchmark antibody ( Bispecific mAb, anti-PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas) therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gremubamab biosimilar, Bispecific mAb: Anti-PcrV type III secretion system; Polysaccharide synthesis locus (Pseudomonas) therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-253-1mg	1mg	Inquiry
GMP-Bios-ab-253-10mg	10mg	Inquiry
GMP-Bios-ab-253-100mg	100mg	Inquiry
GMP-Bios-ab-253-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gremubamab biosimilar, Bispecific mAb: Anti-PcrV type III secretion system; Polysaccharide synthesis locus (Pseudomonas) therapeutic antibody
INN Name	Gremubamab
Target	PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas)
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2019
Year Recommended	2020
Companies	MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Nosocomial pneumonia
Development Tech	na